I t is not possible to discuss immediately the chemistry of, and the therapeutic response to, anti-inflammatory agents which do not possess the steroidal skeleton without properly defining the terms. I t is even more fundamental, but entirely in order, to make some introductory remarks concerning those small molecules, normally dubbed 'drugs', which are designed to combat diseases ofmajor importance and those diseases normally lumped together und er the catch-all phrase 'inflammatory'. At this time it must be recognized that the drugs to be discussed should not be listed under such headings as 'non-narcotic analgesics', 'antipyretics', etc. Even the term 'anti-inflammatory' must be applied with caution since, if properly defined, it reflects only one requirement for a useful drug.
The diseases which we wish to combat adversely affect the joints, bones, Iigaments and connective tissues in many parts of the human body. Further, they are of poor prognosis and their exact etiology is still uncertain. Much human suffering is associated with these diseases since they are deforming and crippling. Consequently, they are of great economic importance since a substantial part of the population is affiicted. In other words, we are not very much concerned with sun burns, but with arthritis and rheumatism to name a few. Although it is true that the etiology of these diseases is still uncertain, nevertheless the combined efforts of chemists, biochemists, and pharmacologists have resulted in the emergence of a reasonable pattern which will hopefully prove rational enough to influence research positively and decisively. This pattern is both illuminating and challenging and shows clearly the multiplicity of factors involved. Figure 1 shows that the acute phase is triggered off by the effect of an irritant which causes an insult to tissues. The irritant may be chemical or physical, or an infective agent. In every case increased vascular permeability results as documented by the appearance of the typical signs 'reddening', 'heat', 'swelling' and 'pain' at the site of the injury. The factors which account for the increase in vascular permeability have been discussed at length previously by Whitehouse and others 1 a and include the pharmacologically active amines, histamine and serotonin; the kinins formed by proteolysis of serum proteins, proteolytic enzymes such as plasmin and kallikrein. An ill-known globulin factor, sometimes called 'rheumatic factor' has also been described.
If we look now at this very rudimentary scheme it becomes apparent that one should define drugs which combat any part of the normal inflammatory response as truly 'anti-inflammatory'. However, those substances which interfere with the secondary and highly undesirable processes which induce the self-perpetuating chronic diseases should, more properly, be called 'anti-rheumatic' or 'anti-arthritic'.
It follows logically that anti-inflammatory drugs as defined can hardly be expected to provide more than symptomatic therapy. In order to make them truly useful 'anti-rheumatic' agents they should show a multiplicity of other effects such as, for instance, stabilization of lysosomal membranes, restoration of proper cellular energy transfer and balance, inhibition of proteolytic enzymes or possibly even immuno-suppressant activity. Lacking, but most important, is the characterization of the true etiological agent or agents which then, in turn, would permit an all-out effort towards the discovery of truly curative anti-rheumatic drugs. Having considered briefly the impressive difficulties in rationale, attention must now be directed to the complexities which confront us if we setout to find an anti-inflammatory and anti-rheumatic agent. Unfortunately, most experimental animals do not suffer from connective tissue diseases and pharmacologists are thus forced to employ models, hoping that their findings in experimental animals inflicted with various conditions simulating certain phases of the inflammatory process and response may become applicable to man. A whole battery of tests both acute and ehrenie is normally employed to evaluate potential drugs. Some of the screens are described below: Having thus set the stage properly, I can now turn to the major topic of this review. A study of the Iiterature may easily Iead the novice in this complex field to the erroneous conclusion that active anti-inflammatory agents and effective anti-rheumatic drugs are available in abundance. The reality is grim. Since the introduction of salicyclic acid in 1876 the research efforts in the entire world over more than 90 years (including the ever escalating efforts in this area over the past 20 years) have not yielded more than a few drugs which have proven themselves clinically in the management of rheumatic disease ( cf. Figure 2) . From this enumeration it already becomes apparent that anti-rheumatic drugs can be very roughly classified into two major categories: acidic and basic. While knowledge accumulates on acidic agents and possible receptor sites are even discussed, very little is known about the basic compounds. And although chloroquine has highly undesirable toxic manifestations, in particular, the unfortunate retinopathic effect, it nevertheless is anti-rheumatic in man.
I t would be preposterous to rehash all the chemical aspects of these five agents. Their chemistry and pharmacology has been amply discussed in the literature. As far as phenylbutazone is concerned, the comprehensive review by von Rechenberg 2 is unsurpassed. I am, therefore, only going to mention a few of the less well-known facts about these drugs. 1. The urinary metabolites of Aspirin® in man have been identified 3 : they are salicyluric, gentisic and salicylic acids (Figure 3 ). Figure 4 gives a short summary of these findings.
The extraordinary differences in the half-life of these drugs in blood plasma in various species are very interesting. Data are given in Table 1 which also shows how difficult extrapolation from experimental animals to man can be.
Intensive structure-activity relationships in the series of pyrazolidin-3,5-diones have been published, for instance, by Schonhafer and Ojurmah 19 and by Dayton 18 . In passing it is noteworthy that there exists a definite relationship in man between pKa and anti-rheumatic activity. In general, it has been found that those derivatives of higher acidity than pKa 4·0 are no Ionger anti-rheumatic but uricosuric. The result of this research is the uricosuric agent Sulfinpyrazone or Anturane® (PKa 2·8) which is shown below tagether with another drug specific for the treatment of gout.
JAMA 187, 2 20 (1964) Although among the oldest non-steroidal anti-rheumatic drugs, phenylbutazone and oxyphenbutazone are by no means obsolete. The scientific and patent Iiterature shows dearly the continued interest in this dass. Some of the examples of this dass of drugs are given below. 
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Arzneimittel Forschung 16,1211 Forschung 16, (1966 We can now turn our attention to one of the latest additions to the Iist of useful anti-rheumatic agents, namely indomethacin or Indocin ®. The discovery of this agent has been adequately described by Tsung-Ying Shen 2 0 in the excerpts of the International Symposium on Non-steroidal Antiinflammatory Drugs. The first synthesis was published by the Merck group in 1963 21 and already at the time of publication more than 350 compounds had been synthesized. Various alternative syntheses have been described in the patent literature 22 • In general, mono-or di-substituted hydrazines are condensed with suitably substituted y-ketoacids and the hydrazones subjected to the Fischer indole cydization ( Figure 5 ).
Alternatively, 3-indolylacetic esters were acylated using sodium hydride in dimethylformamide (see, e.g. Figure 6 ). The utilization of the t-butyl ester, easily removable by heating, is especially advantageaus in view of the lability of the N-acyl groups in the indole series under mildly alkaline or acidic conditions.
In addition to the syntheses by the Merck group also other approaches have become known. In 1965 Makato Takahashi 23 reported the synthesis of 2-methyl-5-methoxy-3-indolylacetic acid via quinoline intermediates In 1966, Kowa Ltd. 24 in Japan claimed in a patent the synthesis of indomethacin by cyclization of 3-(2' -p-chlorobenzoylamino-5' -methoxyphenyl)levulinic acid (Figure 8 ). The study ofa wide variety ofindomethacinanalogues has yielded surprisingly few equipotent substances. As a matter of fact, it appears that the structure is fairly specific and rather sensitive in the negative sense to molecular manipulations. Only the corresponding p-chlorobenzyl analogue shows a pharmacodynamic pro:file similar in nature to that of indomethacin. As Sarett and Shen 25 disclosed [ at the International Symposium on Inftammation held in Freiburg (Germany)] the compounds shown in Figure 9 are all less active, including the isosteric
Recently, however, the Merck group has prepared the indene analogue of indomethacin and has shown that the cis-form has about one half the activity of the latter. The trans-form is about one tenth as active. The synthesis of the indene analogue and its tX-methyl derivative is shown in Figure J0 itself and its cx-methyl analogue the correct representation is that given in Figure 11 . Based on these results a speculative receptor site has been postulated20 the biological importance of which may be considerable ( cf. Figure 12) .
The metabolism of indomethacin in various species including man has been studied and clarified 27 -29 • In rats, dogs and other laboratory animals, indomethacin is largely metabolized to its deacylated and demethylated derivatives, excreted as such or as their glucuronide conjugates. In man, the major urinary metabolite is the unchanged drug or its glucuronide. These metabolites have been synthesized 28 and have been found to be inactive ( cf. Figure 13 ).
Let us turn now our attention to chloroquine. This compound has found extensive use as an anti-malarial agent. However, during World War II it was observed that this agent showed definite anti-rheumatic properties upon prolonged and chronic administration although the onset of action /CH2COOH lH2COOH Figure 14) . M. W. Whitehouse has advanced the speculation 1 that the simultaneaus oxidative metabolism involving both the quinoline nitrogen and the terminal side-chain nitrogen followed by degradation of the side chain 'would almost certainly lead to products which would inhibit ATP formation to some degree by inhibiting electron transport in mitochondria'. Since only a small fraction of the administered drug would be expected to undergo this complex sequence, considerable time would elapse before effective Ievels Glucuronide G l ucuron i de Figure 13 . U rinary metabolites of indomethacin.
of this hypothetical metabolite would be formed. It must be said that there is no evidence in the Iiterature which supports this speculation. Further, one would have to assume that the accumulation of this species would not be interfered with by other enzyme systems.
In view of all the difficulties guidance is sought from biochemistry and immunology. lmmuno-suppressive activity of anti-malarial agents in the treatment of systemic Iupus erythematosus and allergic diseases is recorded in the literature 3 3. Biochemical investigations have failed to demonstrate an appreciable effect on the uncoupling of oxidative phosphorylation and incorporation of 35 In this respect, metabolites (I) and (V) fare better 34 • 35 • Schoenhoefer 36 has shown that chloroquine exerts only moderate inhibitory effects on L-glutamine-n-fructose-6-phosphate aminotransferases. Kurnick and Radcliffe have demonstrated the formation of a DNA-Chloroquine complex in a stoichiometric ratio of l : l 0. This complex apparently inactivates deoxyribonuclease inhibitors 37 • As far as clinical side effects are concerned reversible and irreversible eye darnage is best known. In summary, chloroquine presents a puzzle but also a challenge. The suspicion is aroused that this compound may be acting on the molecular Ievel and influences the rheumatic process in a much more profound 38 manner than most other antirheumatic agents with which the degenerative process progresses under cover of treatment. Therefore, the development of a less toxic and more active, basic anti-rheumatic agent with rapid onset of action is a desirable and potentially rewarding task for research.
The brief outlines on the well documented anti-rheumatic drugs in clinical use will undoubtedly have helped to demonstrate some of the main difficulties and complexities encountered in their screening, development and evaluation. This helps us, however, to exercise the necessary caution in the following discussion on compounds presently in various phases of clinical trial and particularly on those substances which may become drugs of the future.
In Figure 15 are given the structures of those substances which are presently under clinical trial or which have even already been marketed in a limited number of countries. However, the true value of these drugs has not yet Figure 16 ). Another route involves an interesting rearrangement of aryloxybenzylimines (see, e.g. Figure 17 ). Still other pathways 40 u leading to mefenamic acids involve the synthesis of aryl-substituted quinazolinediones, dibenzodiazocinediones and the like followed by alkaline hydrolysis ( Figure  18 ). The synthesis ofthe starting materials employs the same aryl-rearrangement as mentioned before (see, e.g. Figure 19 ). The metabolism of mefenamic and flufenamic acids has been reported 42 •
•
The urinary metabolites of mefenamic acid in man are the 3'-alcohol and rnrcoo K ... + ~Br Figure 16 . The synthesis of fenamic acids.
carboxylic acid ( cf. Figure 20) . The urinary metabolites of flufenamic acid in man are hydroxylated derivatives which are either excreted as such or in the form of glucuronides. The latter are labile towards alkali (Figure 21 ). A receptor site very similar to that proposed for indomethacin has been put forth for the fenamic acids 44 • The biological significance of this hypothesis is uncertain. Extensive studies on structure-activity relationship have been published56· 57 . I t appears that monosubstitution of the benzene ring in the quinoline moiety by halogen, alkoxy and trifluoromethyl in the 7-position provides the most active compounds. The position of the ester function is important. The ortho isomer is at least four times more active than the meta or para analogues in the edema test used by the French workers 58 . Loss or reduction of activity is seen when the ester is converted to the free acid, amide, methylketone or hydrazide. The synthesis of these substances offers no new chemistry and is amply documen ted in the patent ljterature 5 9 a-i.
The developments in the series of arylcarboxylic acids have led to similar studies in the area of arylacetic acids. Some of these agents, shown in and particularly the dextro-rotatory form has been described by Shen and collaborators at Merck 60 • 61 • The compound is apparently most active in the carrageenin edema essay, having an ED 50 of 0·3 mg/kg p.o. 60 lt is ofinterest to note that the active (+)-form also has the (S)-configuration possessed by indomethacin. The synthesis of the new agent and many ofits analogues has appeared in two patents 62 • 63 and proceeds via substituted acetophenones according to the scheme outlined in Figure 24 . No toxicological and clinical data have so far been presented. lbufenac, 4-isobutyl-phenylacetic acid, was first reported by Adams and coworkers to have 'anti-inflammatory properties' 64 • lts synthesis was Figure 24 . The synthesis of 3-chloro-4-cyclohexyl-oc-methylphenylacetic acid.
described in the patent literature 65 a-c. Clinical trials indicated initial efficacy in arthritic patients at one half the dose of Aspirin® 67 • Caution was indicated after it was found that the drug induced hepatotoxic effects upon chronic administration as weil as an elevation of serum transaminases in 20-30 per cent of all cases 66 • The corresponding oc-methyl-isobutyl-phenylacetic acid has been described recently 68 • The substance has been named 'Ibuprofen' and is approximately 10 times more active than ibufenac and 20 times more potent than Aspirin® in the u.v. erythema essay. Its optical resolution has been effected and, interestingly enough, no difference in activity has been noted between the pure enantiomers. This contrasts sharply with the findings by the Merck group on other aryl-a-methyl-acetic acids. The urinary metabolites of ibuprofen in man have been characterized and are found tobe both the dextro-rotatory enantiomers 68 (Figure 25) .
The first clinical report concerning 20 patients with rheumatoid arthritis has appeared 69 • Ibuprofen, in this double-blind study with doses up to 900 mg daily for 7-14 days proved to be ineffective. p-Anilino-phenylacetic acid 74 has shown high activity in both the carrageenin and u.v. edema tests. The substance is also active in the adjuvant arthritis test. R.P. 16·091 75 · 76 has been found active in the carrageenin granuloma, carrageenin edema and u.v. erythema tests. It also has analgesic and anti-pyretic properties and in three-month toxicity sturlies in dogs and rats, a 'no-effect safe level' was seen at 60 mgfkgfday. Symposium in Milan in 1964 85 . Since then the chemistry of benzydamine has been published 86 , and its absorption and elimination in mice, rats, dogs and man has been studied 87 . It appears that benzydamine, upon oral administration to man, leads to prolonged blood plasma levels at the dose compound has been described in a number of patents 90 and in a recent publication by Smuszkovicz and coworkers 91 • It proceeds normally by the application of the Fischer indole synthesis to the phenylhydrazone of deoxyanisoin. Alternative routes involve the condensation of aniline with p-anisoin. The pharmacology of the drug has been published 92 • The oral potency is apparently very much dependent upon the vehicle employed. The intrinsic activity in animals is reflected by efficacy in the adjuvant treated animals as well as in the carrageenin-induced edema 93 • No clinical studies evaluating the anti-arthritic activity of Indoxole have so far been published. The suppressive effects of the agent in crystal-induced synovitis in man has been the subject of a study and it has been shown that a large dose of 3 X 800 mg/13 hours produces measurable Ievels of Indoxole in serum and synovial fiuids of patients. Another agent reported to be effective in the clinic is Armour's 5-amino-1-phenyl-1-(H)-tetrazole (Fenamole). The activity of Fenamole has been or metazamide may be mentioned here 101 • This compound is active in standard pharmacological anti-inflammatory tests. The synthesis of compounds of this dass can be accomplished in a number of ways. Chemically most interesting is the route outlined in Figure 28 . granuloma pouch test. Most prominent in this respect appears to be SU 15 335. The utilization of a p-fluorophenyl-substituted pyrazole as part of an anti-arthritic molecule is not new. Some of the most potent cortisone analogues display this feature 103 as shown in the above structure. I t will indeed be very interesting to learn more about SU 15 335.
Another CIBA-development 1s 'Glyvenol' (CIBA 21401-Ba). This In vivo, anti-allergic properties against systemic anaphylaxis and activity in the dextran-induced edema test were seen. The future fate ofthis agent is ofinterest in the light ofits unusual structure and its interesting biochemical pattern. Finally, I should like to mention that immuno-suppressive agents and their potential anti-rheumatic properties receive increasing attention. This is based upon the suggestion that rheumatoid arthritis may conceivably result from a disturbance of endogenous immune mechanisms. The availability of the adjuvant arthritis test has made it possible to screen immunosuppressives relatively simply. In this way some of the interesting substances described above were discovered. I.C.I. 43 823 prevents secondary lesions in the rat, but is not effective against the primary lesions. I.C.I. 47 776 inhibits the development of polyarthritic lesions and auto-immune syndromes in the rat 105 . U nfortunately, no clinical reports on these substances have so far appeared. It is to be hoped that the development which started with Aspirin®, and led to a variety of drugs with definite beneficial clinical effects such as phenylbutazone and indomethacin, will eventually result in the discovery of truly curative and causal agents.
